# APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

> **NCT04657861** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 36 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** APRIL CAR-T cells

## Key facts

- **NCT ID:** NCT04657861
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-03
- **Primary completion:** 2024-08-20
- **Final completion:** 2027-08-20
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2022-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657861, "APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04657861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*